ZEISS uses its technology, expertise, and commitment to develop promising solutions which provide lasting help and hope. Intraoperative radiotherapy (IORT) with ZEISS INTRABEAM® offers an alternative to conventional external beam radiotherapy in the fight against breast cancer.
Being diagnosed with breast cancer causes anxiety and stress, which tend to be exacerbated by the treatment and its side effects. These days, however, there is now a highly effective and less invasive therapy option in the form of intraoperative radiotherapy. The radiation is administered in a single, approximately 30-minute dose during the operation directly after the surgical removal of the tumor. This means that the traditional follow-up radiotherapy – which typically lasts about six weeks – can be shortened or, in the best-case scenario, even skipped altogether. Healthy adjacent tissue and skin is left unharmed. That means the efficacy of the treatment remains the same, just with a shorter radiation duration with less radiation exposure.
The clinical study results published in August 2020 provide grounds for optimism, with one-time, targeted intraoperative radiotherapy (TARGIT) using ZEISS INTRABEAM found to be noninferior to external beam radiotherapy (EBRT). There is equal risk of tumor recurrence in the breast; however, the non-breast-cancer mortality is reduced.1
The TARGIT method, using INTRABEAM® from ZEISS, is the result of two decades of interdisciplinary research. The clinical endorsements for the method are motivating the medical technology team at ZEISS to continue working intensively on innovative technological solutions that help doctors to improve their patients’ quality of life. Over 45,000 people have already been treated using the TARGIT method. More than 260 breast cancer clinics in 38 countries have adopted this method.2
1. A minimally invasive entrypoint is created during surgery.
2. The tumor is surgically removed.
3. The suitable applicatoris determined and positioned in the tumor cavity.
4. The tumor bed is irradiated locally for approx. 30 minutes.
- Equal clinical effectiveness
- Lower local recurrence rate (tumor regrowth)
- Significantly shorter radiation duratio
- Less pain in the breast
- Increased quality of life thanks to less exposure
- Better cosmetic results
- Further reduction of resource consumption and of clinic space needed because special rooms are unnecessary and ZEISS INTRABEAM® is highly mobile
- Savings from lower purchase and operating costs
(equivalent to 100 hectares of forest) 3
(can be used instead for childcare, volunteer work, or paid work, for example) 3
(for traveling to clinic) 3
as well as further information about INTRABEAM® from ZEISS can you see here.
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.
- 1 https://www.zeiss.com/meditec-ag/media-news/press-releases-hcp/2020/targit-a-breast-cancer-study.html
- 2 https://www.nature.com/articles/s41416-020-01233-5
- 3 Annually, if used extensively, only for the UK; https://pubmed.ncbi.nlm.nih.gov/27160842/